US FDA approves Merck's new injectable version of Keytruda

Core Insights - The U.S. Food and Drug Administration has approved a new formulation of Merck's cancer therapy Keytruda, allowing for subcutaneous administration, which enhances convenience for patients [1] Company Summary - Merck's Keytruda is a leading cancer therapy, and the new formulation is expected to improve patient compliance and comfort [1] Industry Summary - The approval of the subcutaneous formulation reflects ongoing innovation in cancer treatment delivery methods, potentially influencing market dynamics and competitive positioning within the oncology sector [1]